METHODS AND COMPOSITIONS FOR TREATING VIRAL INFECTIONS AND SEQUELAE THEREOF

1 . A method for treating or ameliorating a coronavirus infection, comprising administering a composition that comprises a cultured placental adherent stromal cell (ASC), thereby treating or ameliorating a coronavirus infection.

2 . A method for treating or ameliorating a complication of a coronavirus infection, comprising administering a composition that comprises a cultured placental adherent stromal cell (ASC), thereby treating or ameliorating a complication of a coronavirus infection.

3 . A method for treating, preventing, or ameliorating a pneumonia, comprising administering a composition that comprises a cultured placental adherent stromal cell (ASC), wherein said pneumonia is associated with a viral infection, thereby treating, preventing, or ameliorating pneumonia.

4 . A method for treating, preventing, or ameliorating a complication of a pneumonia, comprising administering a composition that comprises a cultured placental adherent stromal cell (ASC), wherein said pneumonia is associated with a viral infection, thereby treating, preventing, or ameliorating a complication of pneumonia.

5 - 8 . (canceled)

9 . The method of claim 1 , where said composition is an injected composition.

10 . (canceled)

11 . The method of claim 1 , wherein said placental ASC have been incubated on a 3D substrate.

12 . The method of claim 11 , wherein said placental ASC have been incubated on a 2D substrate, prior to incubating on a 3D substrate.

13 . The method or composition of claim 11 , wherein said 3D culture substrate comprises a synthetic adherent material, wherein said synthetic adherent material is a fibrous matrix.

14 . (canceled)

15 . The method of claim 13 , wherein said synthetic adherent material is selected from the group consisting of a polyester, a polypropylene, a polyalkylene, a polyfluorochloroethylene, a polyvinyl chloride, a polystyrene, and a polysulfone.

16 . The method of claim 11 , wherein said 3D culture apparatus comprises microcarriers disposed within a bioreactor.

17 . The method of claim 1 , wherein said placental ASC is allogeneic to said subject.

18 . The method of claim 1 , wherein the composition is intramuscularly injected.

19 . The method of claim 1 , comprising 100-600 million of said placental ASC, for an adult subject.

20 . The method of claim 1 , wherein said composition comprises:

a. a first pharmaceutical composition, comprising allogeneic placental ASC from a first donor; and

b. a second pharmaceutical composition, comprising allogeneic placental ASC from a second donor, wherein said second donor differs from said first donor in at least one allele group of human leukocyte antigen (HLA)-A or human leukocyte antigen (HLA)-B.

21 . (canceled)

22 . The method of claim 4 , wherein said complication is lung fibrosis.

23 . The method of claim 2 , wherein said complication is systemic inflammatory response syndrome.

24 . The method of claim 1 , wherein said ASC express a marker selected from the group consisting of CD73, CD90, CD29 and CD105.

25 . The method of claim 1 , wherein said ASC do not express a marker selected from the group consisting of CD3, CD4, CD11b, CD14, CD19, and CD34.

26 . The method of claim 1 , wherein said ASC do not express a marker selected from the group consisting of CD3, CD4, CD34, CD39, and CD106.

27 . The method of claim 26 , wherein less than 50% of said ASC express CD200.